Vic hosts an insightful discussion with Joel Portice, CEO of egnite, delving into the transformative role of data and AI in revolutionizing cardiovascular care. Joel shares his journey of leading five successful healthcare data companies, including the genesis and rapid growth of egnite, spun out from Edwards Life Sciences. They explore how egnite's flagship platform, Cardio Care, uses advanced analytics, machine learning, and AI to identify and manage cardiovascular patients, saving lives daily. The conversation also covers challenges in healthcare innovation, the impact of early detection, and how their subscription model bridges hospitals and industry partners to improve patient outcomes and accelerate clinical trials.

Research Paper:

Acute Valve Syndrome in Aortic Stenosis study published in Structural Heart Oct 2024

Contact Joel:

egnite website: https://egnitehealth.com/

Email: joel.portice@egnitehealth.com

Linkedin: LinkedIn

00:00 Intro: Introduction to Joel Portice and the final show of the year

00:14 Guest Introduction: Vic introduces Joel Portice, highlighting his experience in healthcare data and startups

01:10 Background: Joel discusses his 25+ years in healthcare data and the genesis of his first company acquired by UnitedHealth Group

03:59 Data in Healthcare: Transition to using advanced analytics and informatics to improve patient care at UnitedHealth Group

05:53 Building Companies: Lessons from Joel's leadership of five successful data companies in healthcare

08:41 Focus in Business: Staying focused on solving specific problems and building strong teams

12:10 egnite's Vision: How egnite spun out from Edwards Life Sciences to focus on cardiovascular health

16:35 Audacious Goals: egnite’s mission to identify all cardiovascular patients in the U.S. and their use of AI and data governance

22:00 Life-Saving Impact: Examples of how Egnite’s software identifies patients needing immediate life-saving therapy

24:00 Business Model: Subscription model for hospitals and partnerships with industry for clinical trial enrollment and commercial adoption

29:00 Published Research: Importance of early detection and interventions in structural heart disease, supported by egnite’s research

31:20 Technology and AI: Use of NLP, machine learning, and AI to analyze cardiovascular data and predict disease progression

33:40 Challenges in Diagnosis: Issues with misdiagnosis and the importance of follow-up for patients with moderate or severe heart disease

41:00 Future of egnite: Joel outlines the company’s focus on execution and plans for the future, including potential international expansion

44:00 Closing: How to connect with Joel Portice and learn more about egnite’s solutions

HF Site

YOUTUBE
INSTAGRAM
TWITTER
FACEBOOK
LINKEDIN
TIKTOK